Drugs / REP 2165
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02565719 | Mar 2016 → May 2019 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2020-11-02 | Replicor Inc. | Results Replicor announces four presentations at AASLD including NAP target identification and well tolerated efficacy in cirrhotic infection replicor.com ↗
Well tolerated compassionate use of TDF and REP 2165-Mg in a cirrhotic individual with HBV / HDV coinfection, achieving simultaneous clearance of HDV RNA and HBsAg and HBsAg seroconversion (Poster 0827). |
| 2020-03-09 | Replicor Inc. | Results Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection replicor.com ↗
Importantly 78% of participants achieved virologic control of HBV of whom 39% further achieved functional cure. |
| 2019-06-10 | Replicor Inc. | Results Replicor presents final REP 401 data demonstrating persistent functional cure of HBV replicor.com ↗
Moreover, 40% of participants further maintained functional cure, indicating the successful restoration of strong immunological control of their chronic HBV infection in the absence of therapy. |
| 2019-02-11 | Replicor Inc. | Results Replicor to update analysis of high rates of functional cure of HBV at APASL 2019 replicor.com ↗
demonstrating further treatment is no longer required in 85% of patients completing therapy |
| 2018-11-06 | Replicor Inc. | Results Replicor to disclose achievement of high rates of functional cure of HBV at AASLD 2018 replicor.com ↗
Replicor’s poster presentation (Poster 393), to be presented on Friday, November 9, 2018, will showcase the on-going follow-up analysis after removal of all treatment (now beyond 24 weeks in most patients) indicating normalization of liver function |
| 2018-06-18 | Replicor Inc. | Results Replicor demonstrates high rates of persistent functional control of HBV infection following cessation of all therapy replicor.com ↗
Liver function is normal in 92% of these patients. |
| 2017-10-10 | Replicor Inc. | Results Replicor to disclose late-breaking follow-up data from its REP 401 study at AASLD 2017 replicor.com ↗
control of HBV infection (HBsAg, anti-HBs and HBV DNA) and normalization of liver function is currently persisting for up to 24 weeks after withdrawal of all therapy |
| 2017-06-28 | Replicor Inc. | Results Replicor announces publication of its studies on the antiviral activity of NAPs in recognized in vitro models of HBV infection replicor.com ↗
These studies demonstrated that early generation NAPs like REP 2055 had an ability to block viral entry only at high concentrations (5-10μM) while later generation (RNA) NAPs like REP 2139 and REP 2165 had negligible entry effect. |
| 2017-02-20 | Replicor Inc. | Results Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017 replicor.com ↗
With REP 2165, a REP 2139 variant with improved tissue clearance, 6/10 patients have > 4 log reductions in HBsAg with loss occurring in 5 of these patients. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REP 2165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02565719 ↗ |
| Known as | REP 2165-Mg | “REP 2165-Mg = magnesium chelate complex of REP 2165” NCT02565719 ↗ |